Frequently Asked Questions

Nine to eighteen months is typical, from engagement start to full activation. The critical path variables are DEA Schedule I license approval and sponsor site evaluation visit scheduling. We compress the site-controlled work so that when those external gates open, your site is ready.

No. Final site selection is always the sponsor's decision and depends on factors including geographic preference, patient population fit, prior audit history, and the sponsor's competitive process. We actively advocate on your behalf and prepare your site to compete for any available study. We do not guarantee a specific study placement.

No. Pharmaka does not act as a recruiter, marketer, or patient acquisition channel. Patient recruitment for psychedelic studies is typically handled by specialized vendors contracted directly by the sponsor.

Your existing controlled substance handling experience shortens the Schedule I licensure path, sometimes significantly. Sites with Schedule II history have already demonstrated the physical security, storage, and inspection readiness that Schedule I requires. We tailor the engagement scope accordingly.

Yes. For network engagements we offer per-site pricing with tiered volume discounts, plus network-level advisory scope on regulatory strategy, sponsor BD, and audit readiness across the site portfolio.

Pharmaka supports Phase 3 clinical trials in mood, anxiety, and trauma-related indications. Active sponsor relationships include Compass Pathways, Cybin, Transcend Therapeutics, Definium, and MindMed, among others. We do not represent any single sponsor exclusively.

San Francisco Bay Area. We work with sites nationally and travel on-site for evaluations, staff training, and pre-audit visits.

Book a 25-minute introductory call below. We will review your site's readiness, discuss your goals, and determine whether Pharmaka is the right fit.